GeoVax Labs (GOVX) Stock Overview
A clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
GOVX Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
GeoVax Labs, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.92 |
| 52 Week High | US$11.18 |
| 52 Week Low | US$0.73 |
| Beta | 3.44 |
| 1 Month Change | -5.63% |
| 3 Month Change | -29.41% |
| 1 Year Change | -60.31% |
| 3 Year Change | -95.11% |
| 5 Year Change | -99.34% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Gedeptin And GEO-MVA Trials Will Shape Vaccine And Cancer Pipelines
Progress in vaccines and strategic partnerships could drive revenue growth from commercialization and global stockpile opportunities.We Think GeoVax Labs (NASDAQ:GOVX) Needs To Drive Business Growth Carefully
Sep 08
GeoVax: Possible Vaccine Advancements In 2 Big Indications
Aug 08GeoVax adds 16% as journal publishes animal study on ebolavirus vaccine
Jul 28Companies Like GeoVax Labs (NASDAQ:GOVX) Could Be Quite Risky
May 24GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation
Dec 27We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth
Nov 27GeoVax: Expands Immuno-Oncology Pipeline With Clinical-Stage Program
Oct 03We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth
Aug 14Shareholder Returns
| GOVX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.2% | -2.1% | 0.3% |
| 1Y | -60.3% | -11.0% | 10.4% |
Return vs Industry: GOVX underperformed the US Biotechs industry which returned -9.9% over the past year.
Return vs Market: GOVX underperformed the US Market which returned 9.9% over the past year.
Price Volatility
| GOVX volatility | |
|---|---|
| GOVX Average Weekly Movement | 18.4% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: GOVX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GOVX's weekly volatility has decreased from 28% to 18% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 17 | David Dodd | www.geovax.com |
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
GeoVax Labs, Inc. Fundamentals Summary
| GOVX fundamental statistics | |
|---|---|
| Market cap | US$12.80m |
| Earnings (TTM) | -US$24.50m |
| Revenue (TTM) | US$5.59m |
Is GOVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GOVX income statement (TTM) | |
|---|---|
| Revenue | US$5.59m |
| Cost of Revenue | US$24.64m |
| Gross Profit | -US$19.05m |
| Other Expenses | US$5.45m |
| Earnings | -US$24.50m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.77 |
| Gross Margin | -340.71% |
| Net Profit Margin | -438.16% |
| Debt/Equity Ratio | 0% |
How did GOVX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/20 07:57 |
| End of Day Share Price | 2025/06/18 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GeoVax Labs, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| null null | CG Capital |
| Jason Kolbert | D. Boral Capital LLC. |